98 related articles for article (PubMed ID: 2872803)
21. Overall safety of terazosin as an antihypertensive agent.
Sperzel WD; Glassman HN; Jordan DC; Luther RR
Am J Med; 1986 May; 80(5B):77-81. PubMed ID: 2872812
[TBL] [Abstract][Full Text] [Related]
22. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
[TBL] [Abstract][Full Text] [Related]
23. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Titmarsh S; Monk JP
Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
[TBL] [Abstract][Full Text] [Related]
24. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
Itskovitz HD
Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of terazosin in the treatment of essential hypertension in blacks.
Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
Weber MA; Cheung DG; Laddu AR; Luther RR
Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Hayduk K; Schneider HT
Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension.
Black HR; Chrysant SG; Curry CL; Frishman WH; Grimm RH; Lasseter KC; Okun R; Pool JL; Raizada V; Vlachakis ND
J Clin Pharmacol; 1992 Apr; 32(4):351-9. PubMed ID: 1349028
[TBL] [Abstract][Full Text] [Related]
29. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
Holtzman JL; Kaihlanen PM; Rider JA; Lewin AJ; Spindler JS; Oberlin JA
Arch Intern Med; 1988 Mar; 148(3):539-43. PubMed ID: 3277569
[TBL] [Abstract][Full Text] [Related]
30. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
Lytle TB; Coles SJ; Waite MA
J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
[TBL] [Abstract][Full Text] [Related]
31. [Pressure and metabolic effects of terazosin in essential hypertension].
Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
[TBL] [Abstract][Full Text] [Related]
32. Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
Jackson B; Morgan TO; Gibson J; Anderson A
Drugs; 1987; 34 Suppl 3():109-19. PubMed ID: 2894971
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
Liu H; Liu P; Mao G; Chen G; Wang B; Qin X; Na Y; Liu Z; Wang X; Xu X
Urology; 2009 Jul; 74(1):130-6. PubMed ID: 19371934
[TBL] [Abstract][Full Text] [Related]
34. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
Silke B; Guy S; Humphreys JE
J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
[TBL] [Abstract][Full Text] [Related]
35. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
37. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
[TBL] [Abstract][Full Text] [Related]
38. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
Torvik D; Madsbu HP
Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
[TBL] [Abstract][Full Text] [Related]
39. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
40. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
